首页> ACS medicinal chemistry letters> Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.

Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.

导出 OA

翻译打印收藏纠错

第一作者： Liangqin,Guo

第一单位： Departments of Medicinal Chemistry, Discovery Pharmaceutical Sciences, Pharmacokenetics Pharmacodynamics Drug Metabolism, Diabetes Research, and Cardiometabolic Disease, Merck & Co., Inc., MRL , 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States.

作者： Liangqin,Guo ^[1] ; Dann L,Parker ^[1] ; Yi,Zang ^[1] ; Ramzi F,Sweis ^[1] ; Weiguo,Liu ^[1] ; Edward C,Sherer ^[1] ; Nicole,Buist ^[1] ; Jenna,Terebetski ^[1] ; Terri,Kelly ^[1] ; Randal,Bugianesi ^[1] ; Birgit T,Priest ^[1] ; Karen H,Dingley ^[1] ; Xiaofang,Li ^[1] ; Stan,Mitelman ^[1] ; Gino,Salituro ^[1] ; Maria E,Trujillo ^[1] ; Michele,Pachanski ^[1] ; Melissa,Kirkland ^[1] ; Mary Ann,Powles ^[1] ; George J,Eiermann ^[1] ; Yue,Feng ^[1] ; Jin,Shang ^[1] ; Andrew D,Howard ^[1] ; Feroze,Ujjainwalla ^[1] ; Christopher J,Sinz ^[1] ; John S,Debenham ^[1] ; Scott D,Edmondson ^[1] ; Ravi P,Nargund ^[1] ; William K,Hagmann ^[1] ; Derun,Li ^[1]

作者单位： Departments of Medicinal Chemistry, Discovery Pharmaceutical Sciences, Pharmacokenetics Pharmacodynamics Drug Metabolism, Diabetes Research, and Cardiometabolic Disease, Merck & Co., Inc., MRL , 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States. ^[1]

关键词 GPR142 agonists glucose-stimulated insulin secretion (GSIS)solubility triazole type 2 diabetes mellitus (T2DM)

DOI 10.1021/acsmedchemlett.6b00314

PMID 27994747

发布时间 2020-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交